U.S. stock market midday update: FDA approval and expansion plans fail to boost, BioRestorative Therapies down 23.78%

U.S. Stock Market Midday Update Biorestorative Therapies fell 23.78%. Based on recent key news: On November 17, BioRestorative Therapies announced it received a Type B meeting designation from the FDA. Although this news is generally viewed as positive progress, the market reacted negatively, leading to a significant drop in stock price. On November 17, the company announced plans to expand into the cervical pain treatment field and appointed an experienced leader in the biocosmetics sector. Despite these strategic moves showing growth potential, they failed to boost investor confidence. On November 17, analyst Okunewitch rated the stock as a buy, but his optimistic outlook did not prevent the stock price from falling, due to the historically low average return of his recommended stocks. The regenerative medicine field is highly competitive and the market is volatile. Stocks with High Trading Volume in the Industry Precision Science rose 17.77%. Based on recent key news: On November 20, Abbott announced it would acquire Precision Science for approximately $21 billion, with a purchase price of $105 per share, a 21.8% premium over the previous day's closing price. This news drove Precision Science's stock price up by 17.6%. Source: Zhitong Finance On November 19, market rumors surfaced about Abbott negotiating to acquire Precision Science, causing Precision Science's stock price to soar by 24%. Analysts believe the acquisition valuation needs to reach 6 to 7 times future sales. Source: Zhitong Finance On November 20, Abbott confirmed the acquisition of Precision Science, expecting the transaction to be completed in the second quarter of 2026. This move will enhance Abbott's position in the rapidly growing cancer diagnostics market. Source: MarketWatch The cancer diagnostics market is growing rapidly, attracting mergers and acquisitions. Regeneron Pharmaceuticals rose 5.04%. Based on recent key news: On November 19, Regeneron Pharmaceuticals announced that its ophthalmic treatment Eylea HD received FDA approval for the treatment of macular edema following retinal vein occlusion. This approval boosted the stock price as market demand for the drug is expected to increase. Source: Reuters On November 20, analyst Carter Gould maintained a buy rating on Regeneron and set a target price of $740. The analyst's positive rating and target price increase boosted market confidence, driving the stock price up. Source: TipRanks On November 19, the European Commission approved Regeneron's PD-1 inhibitor Libtayo as an adjuvant treatment for patients with high-risk recurrent cutaneous squamous cell carcinoma. This approval expanded Libtayo's indications in the EU, further enhancing market confidence in Regeneron. Source: RTTNews Recent favorable policies in the biopharmaceutical industry have led to significant capital inflows AbbVie fell 1.02%. Based on recent news, On November 18, AbbVie announced that its new drug Epkinly received FDA approval for the treatment of follicular lymphoma. This news had a positive impact on the stock price, but concerns about safety warnings led to price volatility. On November 17, AbbVie announced that its new drug LUPRON DEPOT received approval from Health Canada for the treatment of prostate cancer. Although this news was favorable for the company's outlook, it failed to significantly boost the stock price. On November 18, Evercore ISI analyst Gavin Clark-Gartner maintained a buy rating on AbbVie with a target price of $222. However, the market reacted lukewarmly to this rating, and the stock price did not see a significant increase. The pharmaceutical industry has shown stable performance recently, with regulatory dynamics having a significant impact. Stocks ranked at the top of the industry by market capitalization Amgen fell 1.05%, with increased trading volume. Based on recent key news: On November 19, the U.S. FDA granted full approval for Amgen's Imdelltra drug for extensive-stage small cell lung cancer. The drug demonstrated significant survival extension effects in phase III clinical trials, reducing the risk of death by 40%, which should have boosted market confidence, but the stock price still declined. On November 19, Amgen's press release emphasized the approval of Imdelltra and its innovative position in the biotechnology field; however, concerns about potential side effects may have affected investor sentiment. On November 20, the market held a cautious attitude towards the overall high valuation and future growth potential of the biotechnology industry, which may lead investors to take profits in the short term, impacting stock performance. The biotechnology industry is facing valuation pressure